Achieving Success Together
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost-effective new products for its partners and their patients. With a focus on Safer to Use™ formulations, Altus’ technologies include Intellitab™ abuse deterrent technology, Flexitab™ breakable extended release tablets and SmartCelle™ technologies for intravenous or oral delivery of low solubility large and small molecules.
Algorithme Pharma is conducting stage 1 clinical trials of PPP001 in collaboration with Tetra Bio-Pharma.
Crescita (TSX: CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin.
Tetra Bio-Pharma and IntelGenx Corp. have a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol XL – PPP002 for the management of anorexia and chemotherapy-induced nausea and vomiting.
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. The Company’s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other counties through local distributors. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties.
McGill University is collaborating with Tetra Bio-Pharma on an NSERC (National Sciences and Engineering Research Council) funded research study to develop consumer products containing cannabinoids.
NSERC – The National Sciences and Engineering Research Council of Canada connects industry players with world-firsts in knowledge and the people behind them, fueling R&D and leading to firsts in the marketplace. They have granted Tetra Bio-Pharma research funding related to the development of consumer products in collaboration with McGill University.
The Ontario Lung Association is a not-for-profit organization dedicated to helping all Canadians breathe. Their community of donors, patients, researchers, volunteers and professional staff work to promote healthy breathing, support those living with lung disease and find future solutions.
Panag Pharma is a subsidiary of Tetra Bio-Pharma and focuses on two products, PPP003 and PPP004 for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both product in the USA in 2014 was estimated at over US$5.5 billion.
Tetra Bio-Pharma and The New Brunswick Health Research Foundation are investing a combined $1 million, $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB). The Chair will focus on the study of biochemistry, medicinal use and pharmacology of cannabis. This research will expand UNB’s commitment to research and innovation in the field of natural products and biomedical, health and life sciences – adding to its reputation as a leader in natural products’ research.